Best Read Articles on Biosimilars in 2021
News about interchangeable Semglee (insulin glargine-yfgn) was among the most read in 2021.
Prime Therapeutics Adds the Biosimilar Semglee to Preferred Formulary
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
Read more
OptumRx Excludes the Diabetes Biosimilar Semglee from Formulary
OptumRx will favor the reference product Lantus on the Premium Formulary. The organization also released coverage information about other newly approved therapies.
Read more
Survey: Biosimilars are Gaining Momentum Among Payers
AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.
Walgreens Offering Biosimilar and Interchangeable Insulin Semglee
Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.
Study: Medicare Part B Reimbursement Hinders Biosimilar Uptake
A reimbursement policy similar to that used for branded and generic drugs would have saved $1.6 billion from 2015 to 2019.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 5th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 5th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
